TOP TEN perturbations for NM_000203 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000203
Selected probe(set): 205059_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000203 (205059_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):-3.256833
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 ?C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 ?C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 ?C in 6-well plates.

prostate cancer study 8 (p. canc) / prostate cancer study 8 (psfmc)

Relative Expression (log2-ratio):1.9092569
Number of Samples:3 / 5
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (psfmc)
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy.

doxorubicin study 3 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):1.8713131
Number of Samples:2 / 2
Experimental doxorubicin study 3
MCF7 cells treated with 2uM doxorubicin for 24 hours. ATC code:
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

breast cancer study 3 / normal mammary gland tissue

Relative Expression (log2-ratio):-1.6673965
Number of Samples:17 / 7
Experimental breast cancer study 3
Breast basal tumor samples.
Control normal mammary gland tissue
Normal breast tissue samples.

EBNA2 overexpr. study 1 (24h) / control virus transfected EREB2-5 cell sample (24h)

Relative Expression (log2-ratio):-1.5911589
Number of Samples:3 / 3
Experimental EBNA2 overexpr. study 1 (24h)
EREB2-5 cell line stably transfected with the chimeric Epstein-Barr virus-encoded nuclear antigen 2 (EBNA2) and control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene and . CAT was used as a negative control. Briefly, before the CAT and EBNA2 induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline and estrogen was added. Expression of EBNA2 was induced after addition of estrogen and expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Because EBNA2 is essential for the proliferation of EBV-infected cells, EREB2-5 cells grow only in the presence of estrogen. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline.
Control control virus transfected EREB2-5 cell sample (24h)
EREB2-5 cell line stably transfected with control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene. CAT was used as a negative control. Briefly, before the CAT induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline was added. Expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Estrogen withdrawal leads to the inactivation of EBNA2, resulting in cell cycle arrest. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline.

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):-1.5561037
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.

hair follicle growth study 1 (P5) / hair follicle growth study 1 (P0)

Relative Expression (log2-ratio):1.5207129
Number of Samples:3 / 3
Experimental hair follicle growth study 1 (P5)
Dermal papilla cells isolated from occipital scalp hair follicles obtained and cultured subsequent in two dimensional culture. Samples were taken at passage 5.
Control hair follicle growth study 1 (P0)
Dermal papilla cells isolated from occipital scalp hair follicles obtained and cultured subsequent in two dimensional culture. Samples were taken directly after cell explant outgrowth.

PCB153 study 1 (24h; 70uM) / PCB153 study 1 (30min; 70uM)

Relative Expression (log2-ratio):1.4911156
Number of Samples:3 / 2
Experimental PCB153 study 1 (24h; 70uM)
HK-2 cell line (8th generation) were treated with 2,2?,4,4?,5,5?-hexachlorobiphenyl (PCB153) for 6 hours. Cells were grown in keratinocyte-serum free medium supplemented with 5ng/ml recombinant epidermal growth factor, 0.05mg/ml bovinepituitary extract and 1x penicillin-streptomycin. ATC code:---
Control PCB153 study 1 (30min; 70uM)
HK-2 cell line (8th generation) were treated with 2,2?,4,4?,5,5?-hexachlorobiphenyl (PCB153) for 30 minutes. Cells were grown in keratinocyte-serum free medium supplemented with 5ng/ml recombinant epidermal growth factor, 0.05mg/ml bovinepituitary extract and 1x penicillin-streptomycin. ATC code:---

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):1.4830751
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

ALL study 3 (8d) / ALL study 3 (0d)

Relative Expression (log2-ratio):1.4659042
Number of Samples:2 / 2
Experimental ALL study 3 (8d)
Peripheral blood samples from children with de novo acute lymphoblastic leukemia. Samples were taken 8 days after remission-induction therapy (RIT).
Control ALL study 3 (0d)
Peripheral blood samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT).